Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | TNF | P01375 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29611861 | 0.88 | ALOX5AP (0.47) | CNR2ALDH1A1MEN1KMT2ATNF | |
| SCHEMBL7421689 | 0.88 | ALOX5AP (0.49) | ALDH1A1MEN1KMT2ATNFKDM4E | |
| SCHEMBL687131 | 0.88 | ALOX5AP (0.47) | CNR2ALDH1A1MEN1KMT2ATNF | |
| SCHEMBL7417850 | 0.87 | L3MBTL1 (0.40) | CNR2ALDH1A1MEN1KMT2ATNF | |
| SCHEMBL7427533 | 0.86 | ALOX5AP (0.46) | ALDH1A1MEN1KMT2AL3MBTL1ALOX5AP | |
| SCHEMBL7417956 | 0.86 | ALOX5AP (0.48) | ALDH1A1MEN1KMT2AKDM4EL3MBTL1 | |
| Hydrochloric Acid SCHEMBL7477963 | 0.86 | L3MBTL1 (0.39) | CNR2ALDH1A1MEN1KMT2ATNF | |
| SCHEMBL7707842 | 0.85 | ALOX5AP (0.45) | ALDH1A1MEN1KMT2AL3MBTL1ALOX5AP | |
| SCHEMBL7420327 | 0.85 | ALOX5AP (0.46) | TNFKDM4ENOD2NOD1L3MBTL1 | |
| SCHEMBL7420140 | 0.85 | SLC22A12 (0.53) | ALDH1A1KDM4EALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090053168-A1 | TREATMENTS OF B-CELL PROLIFERATIVE DISORDERS | ZALICUS INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090047243-A1 | COMBINATIONS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | ZALICUS INC. | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047243-A1 | COMBINATIONS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | ADORA2A, PDE4A, PDE4D | CNR2 256/4885ALDH1A1 1368/4885MEN1 1161/4885 |
| US-20090053168-A1 | TREATMENTS OF B-CELL PROLIFERATIVE DISORDERS | BCL6, BCL6B, BCL3 | CNR2 415/4885ALDH1A1 1378/4885MEN1 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.